Phase I expansion study of XMT-1536, a novel NaPi2b-targeting ADC - Preliminary results in Pts with previously treated metastatic OC or NSCLC - Debra L. Richardson MD - Sarah Cannon @Sara...

Phase I expansion study of XMT-1536, a novel NaPi2b-targeting ADC - Preliminary results in Pts with previously treated metastatic OC or NSCLC - Debra L. Richardson MD - Sarah Cannon @Sara...

User Photo
Cancer-News

1 week
11 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Debra L. Richardson, MD - Sarah Cannon discusses Phase I expansion study of XMT-1536, a novel NaPi2b-targeting antibody-drug conjugate (ADC): Preliminary efficacy, safety, and biomarker results in patients with previously treated metastatic ovarian cancer (OC) or non-small cell lung cancer (NSCLC)





ASCO


https://meetinglibrary.asco.org/record/188449/abstract
Up Next Autoplay